Zentalis Pharmaceuticals announced the successful closing of a stock offering, raising approximately $92.6 million in gross proceeds.
The capital raise provides the pharmaceutical company with additional financial flexibility to support its ongoing operations and clinical development pipeline. Further details regarding the pricing, share volume, and specific intended uses of the proceeds were not immediately disclosed.
